[Lucentis in treatment of the wet-form of age-related macular degeneration--two years experience].
In a study group of 114 patients (39 males, 75 females) with mean age of 72, 5 years (from 52 to 89 years) with mean follow-up of 8 month we retrospectively studied the effectivity and safety of intravitreal aplication of ranibizumab = Lucentis in the case of wet form of age-related macular degeneration (AMD). All patients met the inclusion criteria. The treatmet was realized on outpatient basis under strict application protocol. In the follow-up period the visual acuity improved in 66 patients (57%), stabilization was achieved in 17 patients (24.9%). In a group of 31 patients (27.2%) the central acuity deteriorated. There were no peroperative complications. In the postoperative period we observed in 22 patients temporary rise of intraocular pressure, in 21 patients suffusion, and in 3 patients there were subretinal haemorrhages found, in 1 case rupture of RPE and in 1 case anterior ischemic opticopathy was observed. Results observed in this study are in full compliance with PRONTO and PIER studies.
Molnárová
M
M
II. ocná klinika SZU FNsP F. D. Roosevelta, Banská Bystrica. m.molnarova@nspbb.sk
Lesková
V
V
Demský
P
P
Vida
R
R
Izák
M
M
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab